Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Stoke Therapeutics Inc (NASDAQ: STOK) was $34.17 for the day, down -4.02% from the previous closing price of $35.6. In other words, the price has decreased by -$4.02 from its previous closing price. On the day, 3.41 million shares were traded. STOK stock price reached its highest trading level at $38.62 during the session, while it also had its lowest trading level at $33.02.
Ratios:
Our analysis of STOK’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.62. For the most recent quarter (mrq), Quick Ratio is recorded 6.98 and its Current Ratio is at 6.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 08 ’25 when Kaye Edward M. MD sold 25,000 shares for $30.00 per share. The transaction valued at 750,000 led to the insider holds 49,124 shares of the business.
EDWARD M KAYE bought 25,000 shares of STOK for $682,750 on Oct 08 ’25. On Oct 03 ’25, another insider, Kaye Edward M. MD, who serves as the Director of the company, sold 42,461 shares for $25.09 each. As a result, the insider received 1,065,206 and left with 49,124 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1872427648 and an Enterprise Value of 1628270720. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.37 while its Price-to-Book (P/B) ratio in mrq is 5.58. Its current Enterprise Value per Revenue stands at 8.146 whereas that against EBITDA is 38.52.
Stock Price History:
The Beta on a monthly basis for STOK is 1.24, which has changed by 1.6284616 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $37.67, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 51.90%, while the 200-Day Moving Average is calculated to be 160.82%.
Shares Statistics:
STOK traded an average of 1.08M shares per day over the past three months and 1923340 shares per day over the past ten days. A total of 54.72M shares are outstanding, with a floating share count of 46.09M. Insiders hold about 15.88% of the company’s shares, while institutions hold 113.27% stake in the company. Shares short for STOK as of 1759190400 were 10784510 with a Short Ratio of 9.94, compared to 1756425600 on 10737735. Therefore, it implies a Short% of Shares Outstanding of 10784510 and a Short% of Float of 23.79.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.54 and low estimates of -$0.81.
Analysts are recommending an EPS of between $0.48 and -$0.1 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is -$2.92, with 9.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $12M to a low estimate of $3M. As of. The current estimate, Stoke Therapeutics Inc’s year-ago sales were $4.89MFor the next quarter, 10 analysts are estimating revenue of $5.47M. There is a high estimate of $11M for the next quarter, whereas the lowest estimate is $3M.
A total of 11 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $205.8M, while the lowest revenue estimate was $178.39M, resulting in an average revenue estimate of $185.58M. In the same quarter a year ago, actual revenue was $36.55M
